Plain-English translation of NCT04613596 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new drug called for people with advanced lung cancer that has a specific genetic change (KRAS G12C mutation). The study will evaluate whether this medication works better when given by itself or when combined with , an immunotherapy drug that helps your immune system fight cancer. The trial has two parts: an earlier phase to test safety and effectiveness, and a larger phase to compare the combination treatment against alone.
Most people with this specific type of lung cancer don't have good treatment options because their cancer has been hard to target. This medication represents a new approach by directly blocking the faulty KRAS protein that drives these cancers, and researchers want to know if combining it with immunotherapy can help more patients.
You likely qualify if…
You likely don't qualify if…
You would take the new medication by mouth twice daily, either alone or combined with an intravenous immunotherapy infusion given every few weeks, depending on which group you're in. Throughout the trial, you'll have regular clinic visits for blood tests, imaging scans to measure how your cancer is responding, and check-ins about any side effects you experience. The exact length of participation depends on how well the treatment is working and how you tolerate it.
AI-generated summary from trial data · Aug 30, 2026 · Not medical advice
United States